Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Tacrolimus is the drug of choice immunosuppressant in renal transplant (RTx) recipients, but due to its narrow therapeutic index, wider inter and intra patient variability and difficult pharmacogenomics, optimized dose of tacrolimus is difficult to achieve. The study is focused to investigate the cytochrome P450 3A5 (CYP3A5) and ATP-Binding Casette transporter B1 (ABCB1) polymorphisms among RTx recipients in association with daily tacrolimus dose requirements, tacrolimus blood trough levels and clinical outcomes in terms of rejection, co-infections and side effects.
This retrospective cross-sectional study is conducted at Renal transplant Unit of Dow University Hospital, DUHS. A total of 83 subjects who have received renal transplant and on tacrolimus for more than one year have been recruited for genotyping analysis (via primer specific PCR, Gel electrophoresis and RFLP enzymes) of CYP3A5 and ABCB1 polymorphisms in association with pharmacokinetic details of tacrolimus and relevant clinical outcomes.
In this study, 79.8% (n = 64) were males, the mean age of transplant recipients were 37 years while median duration since transplantation was 28 months. 15.6% (n = 10) were pre-emptive transplant while hypertensive nephropathy (42.35%, n = 27) was found to be the most common cause of ESRD in our study. Post transplant Diabetes Mellitus was common in 57.83% (n = 48) of subjects. The mean daily dose of tacrolimus was 2.5 ± 0.5mg, oral predinisolone (15mg) and mycophenolate mofetil (1000mg). The mean tacrolimus blood trough levels were 7.6 ± 3.7 mg/dl, 7.1 ± 2.1 mg/dl and 5.9 ± 3.9 mg/dl at 0, 3 and 6 months, retrospectively. All subjects were tested CYP3A5*1/3 (non-expressors) genotype while homozygous mutants ABCB1 rs1045642 and rs2032582 have considerably higher blood trough concentration levels as compared to heterozygous or homozygous wild type (9.3 ± 1.1 mg/dl versus 6.3 ± 3.2 mg/dl). Significant association of higher neutrophils/ platelets ratio (p ≤ 0.001), higher CRP levels (p ≤ 0.045), frequent infections and hospitalization (p ≤ 0.001) was reported in homozygous mutants ABCB1 rs2032582 while CYP3A5*1/3 non expressors has significantly increased fasting blood sugar levels, hypertriglyceridemia and hyperuricemia.
Our results support the hypothesis that CYP3A5 and ABCB1 polymorphisms have major influence in achieving targeted tacrolimus blood trough levels and polymorphisms may lead to abnormally higher rate of adverse effects which may affect long term graft functions. It is highly recommended that timely detection of theses notable polymorphisms may reduce the titration time in tacrolimus dose optimization thus reducing side effects and improving the outcomes.
